EMFAT
KALV

Emerald Mutual Fund Advisers Trust’s KalVista Pharmaceuticals KALV Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-805,762
Closed -$16.2M – 210
2026
Q1 		$16.2M Sell
805,762
-49,699
-6% -$801K 0.79% 54
2025
Q4 		$13.8M Sell
855,461
-62,514
-7% -$828K 0.67% 67
2025
Q3 		$11.2M Buy
917,975
+149,003
+19% +$2.06M 0.58% 69
2025
Q2 		$8.69M Buy
768,972
+160,759
+26% +$1.97M 0.53% 72
2025
Q1 		$7.02M Buy
608,213
+58,525
+11% +$597K 0.5% 78
2024
Q4 		$4.66M Sell
549,688
-101,292
-16% -$1.05M 0.28% 98
2024
Q3 		$7.54M Buy
650,980
+121,615
+23% +$1.53M 0.39% 84
2024
Q2 		$6.24M Hold
529,365
– – 0.33% 94
2024
Q1 		$6.28M Buy
+529,365
New +$7.06M 0.33% 99
2021
Q4 		– Sell
-136,554
Closed -$2.38M – 225
2021
Q3 		$2.38M Sell
136,554
-269,658
-66% -$5.47M 0.08% 158
2021
Q2 		$9.73M Sell
406,212
-10,000
-2% -$262K 0.32% 107
2021
Q1 		$10.7M Buy
+416,212
New +$10.9M 0.35% 106

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's KALV Position: Q2 2026 in Review

Emerald Mutual Fund Advisers Trust sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 805,762 shares — an estimated $16.2M sold.

Emerald Mutual Fund Advisers Trust first reported a position in KALV in Q1 2021 and held it in 12 quarters. The position peaked at $16.2M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Emerald Mutual Fund Advisers Trust reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 805,762 KalVista Pharmaceuticals shares in Q2 2026, an estimated $16.2M.
  • Emerald Mutual Fund Advisers Trust first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 12 quarters.
  • Emerald Mutual Fund Advisers Trust's KalVista Pharmaceuticals position peaked at $16.2M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2026, filed 5 Aug 2026.